Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme-Reference-Cited by-同舟云学术

Preclinical and clinical implications of TERT promoter mutation in glioblastoma multiforme

Published:2017-10-16 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Jeong Da Eun¹,Woo Seon Rang²,Nam Hyun³,Nam Do‑Hyun¹,Lee Jae‑Ho⁴,Joo Kyeung Min¹

Affiliation:

1. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06531, Republic of Korea

2. Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea

3. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06531, Republic of Korea

4. Department of Anatomy, Keimyung University School of Medicine, Daegu 42601, Republic of Korea

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Role of TRF1 and TRF2 Expression in Non-Small Cell Lung Cancers;OncoTargets and Therapy;2024-06

2. A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors;The Oncologist;2023-08-24

3. From Theory to Practice: Implementing the WHO 2021 Classification of Adult Diffuse Gliomas in Neuropathology Diagnosis;Brain Sciences;2023-05-18

4. Telomerase: A prominent oncological target for development of chemotherapeutic agents;European Journal of Medicinal Chemistry;2023-03

5. A Targeted Next-Generation Sequencing Panel to Genotype Gliomas;Life;2022-06-24